Phase 2 study of sorafenib plus protracted temozolomide in recurrent glioblastoma multiforme.

Trial Profile

Phase 2 study of sorafenib plus protracted temozolomide in recurrent glioblastoma multiforme.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs Sorafenib (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2013 Actual end date changed from Sep 2010 to Dec 2010 as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top